Complement C3

Complement C3

Complement C3 Overview

Molecule Name
Complement C3
Synonyms
Complement C3,CPAMD1
Drug Development Progress
Drugs in Clinical Trials13
Approved Drugs1
Highest Development StageApproved
Target Synonym
Complement C3,Complement Component C3a,Epididymis Secretory Sperm Binding Protein Li 62p,C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1,C3bc,C3adesArg,C3,Complement Component C3b,Complement Component 3,C3a Anaphylatoxin,Prepro-C3,CPAMD1,Acylation-Stimulating Protein Cleavage Product,HEL-S-62p,AHUS5,ARMD9,ASP,C3a,C3b
Background
C3 is the major complement component serum. It is mainly synthesized by macrophages and liver. C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. It is cleaved into two fragments, C3a and C3b. C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.

Complement C3 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Efdamrofusp alfaIBI-302Phase 3 ClinicalAP Biosciences Inc
Diabetic macular oedema; Macular Degeneration; Plaque psoriasis; Wet Macular Degeneration
Details
NGM-621NGM-621Phase 2 ClinicalNGM Biopharmaceuticals Inc
Coronavirus Disease 2019 (COVID-19); Geographic Atrophy
Details
RG-002-C-0106RG-002-C-0106; RG002C0106Phase 2 ClinicalBeijing Xuanjingrui Pharmaceutical Technology Co Ltd, Suzhou Xuanjing Biotechnology Co Ltd
Complement-Mediated Diseases; Glomerulonephritis, IGA; Hemolysis; Nephrotic Syndrome
Details
APL-3007APL-3007Phase 2 ClinicalApellis Pharmaceuticals Inc
Geographic Atrophy
Details
SGB-9768SGB-9768Phase 2 ClinicalSuzhou Sanegene Bio Inc
C3 glomerulopathy; Glomerulonephritis; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Kidney Diseases
Details
KRIYA-825KRIYA-825; VV-14295Phase 2 ClinicalKriya Therapeutics Inc
Geographic Atrophy
Details
ALXN-2030ALXN-2030Phase 2 ClinicalAlexion Pharmaceuticals Inc
Rejection of renal transplantation; Rejection of organ transplantation
Details
LP-005LP-005; RX-001Phase 2 ClinicalLongbio Pharma (Suzhou) Co Ltd
Amyotrophic Lateral Sclerosis; C3 glomerulopathy; Carcinoma, Non-Small-Cell Lung; Complement-Mediated Diseases; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Nephritis; Myasthenia Gravis; Periodontal Diseases; Peripheral Nervous System Diseases; Thrombotic Microangiopathies
Details
ARO-C3ARO-C3; ARO-C-3Phase 2 ClinicalArrowhead Pharmaceuticals Inc
C3 glomerulopathy; Glomerulonephritis, IGA
Details
CG-001CG-001Phase 1 ClinicalChengdu Konjin Co Ltd
Autoimmune Diseases; Hemoglobinuria, Paroxysmal; Myasthenia Gravis
Details
BI-CPhase 1 ClinicalBoehringer Ingelheim International Gmbh
Geographic Atrophy; Retinal Diseases
Details
Ebribafusp alfaADX-097Phase 1 ClinicalQ32 Bio Inc
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Glomerulonephritis, IGA; Kidney Diseases; Lupus Nephritis; Nephrosis, Lipoid
Details
NM3086NM3086; NM-3086Phase 1 ClinicalNovelMed Therapeutics Inc
Hemoglobinuria, Paroxysmal
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
PegcetacoplanAPL-2ApprovedApellis Pharmaceuticals IncAspaveli, Empaveli, SyfovreUnited StatesHemoglobinuria, ParoxysmalApellis Pharmaceuticals Inc2021-05-14
Amyotrophic Lateral Sclerosis; Anemia, Hemolytic, Autoimmune; C3 glomerulopathy; Delayed Graft Function; Geographic Atrophy; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Glomerulonephritis, Membranous; Glomerulosclerosis, Focal Segmental; Hemoglobinuria, Paroxysmal; Kidney Failure, Chronic; Lupus Nephritis; Macular Degeneration; Motor Neuron Disease; Rejection of renal transplantation
Details